Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.

Cancer science - 1 Jan 2024

Morishima Tatsuya, Takahashi Koichi, Chin Desmond Wai Loon, Wang Yuxin, Tokunaga Kenji, Arima Yuichiro, Matsuoka Masao, Suda Toshio, Takizawa Hitoshi

Abstract excerpt

Genetic mutations in the isocitrate dehydrogenase (IDH) gene that result in a pathological enzymatic activity to produce oncometabolite have been detected in acute myeloid leukemia (AML) patients. While specific inhibitors that target mutant IDH enzymes and normalize intracellular oncometabolite level have been developed, refractoriness and resistance has been reported. Since acquisition of pathological enzymatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arachidonic Acid
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 37882467
DOI: 10.1111/cas.15994
PMCID: PMC10823289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.PMID 37882467Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid LeukemiaSemantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in leukemiaSemantic proximity Read ↗

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia.Semantic proximity Read ↗

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.Semantic proximity Read ↗

Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation.Semantic proximity Read ↗

Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.